| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Prostate Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Prostatic Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Genital Diseases, Male | |||||
| Genital Neoplasms, Male | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Prostatic Diseases | |||||
| Urogenital Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| RAD001 | |||||
| Bicalutamide | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Everolimus | |||||
| 6 | More general drug interventions related to this trial | ||||
| Androgen Antagonists | |||||
| Antineoplastic Agents | |||||
| Hormone Antagonists | |||||
| Hormones, Hormone Substitutes, and Hormone Antagonists | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Dana-Farber Cancer Institute | |||||
| Beth Israel Deaconess Medical Center | |||||
| Novartis | |||||
|
